alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Appendix B

Appendix B-15

B

Resources for Vaccines

Vaccine Excipients

y Food and Drug Administration (FDA) Vaccine Package Inserts: https://www.fda.gov/vaccines-blood-biologic

vaccines/vaccines-licensed-use-united-states

y Thimerosal and Vaccines (FDA): https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologic

thimerosal-and-vaccines

y Thimerosal and Vaccines (CDC): https://www.cdc.gov/vaccinesafety/concerns/thimerosal/index.h

y Common Ingredients in U.S. Licensed Vaccines (FDA): https://www.fda.gov/vaccines-blood-biologics/safetyavailability-biologics/common-ingredients-us-licensed-vacc

y Excipients in Vaccines per 0.5 mL dose (Johns Hopkins): https://www.vaccinesafety.edu/components-Excipients.

Interpreting Vaccines from Other Countries

y World Health Organization (WHO) Country Profiles: https://apps.who.int/immunization_monitoring/globalsummar
No. 11-7101.

#### William Morrison, Petitioner v. United States.

565 U.S. 1072, 132 S. Ct. 793,

181 L. Ed. 2d 507,

2011 U.S. LEXIS 8441.

November 28, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Tenth Circuit denied.
No. 11-6722.

#### Eric Wolfe, Petitioner v. United States.

565 U.S. 1019, 132 S. Ct. 561,

181 L. Ed. 2d 405,

2011 U.S. LEXIS 7978.

November 7, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.

Same case below, 442 Fed. Appx. 16.
ID Descriptor L* a* b* c h dL* da* db* dEcmc*

Standard 20045 STANDARD 42.26 6.31 12.38

Tolerance

1

2

3

4

5

6

7

8

9

COMMENTS: NUMBERS ARE FOR REFERENCE ONLY 

Equipment Type HUNTER ULTRA SCAN PRO Setting Mode: Specular Included - Reflectance

UV Filter – OUT UV Lamp OFF

DLA/NAVY SHADE TOLERANCE PROJECT June 22, 2020

Fabric Nomenclature CLOTH, 100% COTTON, JERSEY NU-PD 19031

Shade Number BROWN 3760 Piece/Roll Number 20045
```

[Federal Register Volume 76, Number 13 (Thursday, January 20, 2011)]
[Notices]
[Pages 3608-3609]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-1277]

=======================================================================
-----------------------------------------------------------------------

COMMISSION ON CIVIL RIGHTS

Sunshine Act Notice

AGENCY: United States Commission on Civil Rights.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

DATE AND TIME: Friday, January 28, 2011; 11:30 a.m. EST.

PLACE: Via Teleconference. Public Dial in: 1-800-597-7623. Conference 
ID#: 37792479.

Meeting Agenda

    This meeting is open to the public.

[[Page 3609]]

I. Approval of Agenda.
II. Welcome New Commissioners.
III. Management and Operations:
     Review of transition, order of succession, continuity of 
operations.
     Review of 2011 meeting calendar.
     Staff Director's report.
IV. Program Planning: Update and discussion of projects.
     Cy Pres.
     Disparate Impact in School Discipline Policies.
     Gender and the Wage Gap.
     Title IX--Sex Discrimination in Liberal Arts College 
Admissions.
     Eminent Domain Project.
     NBPP.
V. State Advisory Committee Issues:
     Consideration of Vermont SAC Chair.
     Re-chartering the Alabama SAC.
VI. Approval of Dec. 3, 2010 Meeting Minutes.
VII. Announcements.
VIII. Adjourn.

CONTACT PERSON FOR FURTHER INFORMATION: Lenore Ostrowsky, Acting Chief, 
Public Affairs Unit (202) 376-8591. TDD: (202) 376-8116.
    Persons with a disability requiring special services, such as an 
interpreter for the hearing impaired, should contact Pamela Dunston at 
least seven days prior to the meeting at 202-376-8105. TDD: (202) 376-
8116.

    Dated: January 18, 2011.
Christopher Byrnes,
Delegated the Authority of the Staff Director.
[FR Doc. 2011-1277 Filed 1-18-11; 4:15 pm]
BILLING CODE 6335-01-P
```
#  Box1_Figure  1

#  Box1_Figure  1
JOHN J. ROBERTS

Is being inducted into the Defense Supply Center Philadelphia Hall of Fame this twenty-third day of 

October 2001 for his continuous outstanding mission support from 1972 through 1999. Mr. Roberts 

distinguished himself through his exceptional dedication and the professional manner in which he 

performed throughout his career at DSCP. His hard work, visionary leadership and unyielding 

determination improved the medical supply chain. The processes he developed significantly 

contributed to the health and welfare of military service members, their families, and the millions 

of other beneficiaries who rely on the Department of Defense Healthcare network. He personally 

led the electronic processing revolution, which has become the hallmark of Medical Directorate 

operations, and the model for the entire Department of Defense. Mr. Roberts influenced every facet 

of the Medical Directorate’s electronic and business process transformation. 

Hall of Fame Inductees Page 1 of 1

https://www.troopsupport.dla.mil/about_us/roberts.htm 1/21/2016
<page>   EXHIBIT 32.02

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002




In connection with the Quarterly Report of Morgan Stanley Charter
Millburn L.P. (the ?Partnership?) on Form 10-Q for the period
ended March 31, 2005 as filed with the Securities and Exchange
Commission on the date hereof (the ?Report?), I, Kevin Perry,
Chief Financial Officer, Demeter Management Corporation, the
general partner of the Partnership, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-
Oxley Act of 2002, that, to the best of my knowledge:
(1)	The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents,
in all material respects, the financial condition and
results of operations of the Partnership.









By:    /s/Kevin Perry

Name:		Kevin Perry
Title:	Chief Financial Officer

Date:		May 16, 2005
EX-10.18



 Exhibit 10.18 
  





 
 December 6, 2013 
 Kelly
Connery 
 Re: Promotion to Chief Revenue Officer 

Dear Kelly, 
 On behalf of Bazaarvoice, Inc. (the
“Company”), I am pleased to offer you a promotion to the position of Chief Revenue Officer reporting to Gene Austin, President. In this position, you will be expected to continue to devote your full business time, attention and
energies to the performance of your duties with the Company. Your promotion becomes effective December 9, 2013, provided that you sign and return this letter by such date. Except as set forth herein, the terms of this offer of employment remain
the same as your original offer letter dated February 7, 2012. 
 1. At-Will Employment. You should be aware that your employment
with the Company is for no specified period and constitutes “at-will” employment. As a result, you are free to terminate your employment at any time, for any reason or for no reason. Similarly, the Company is free to terminate your
employment at any time, for any reason or for no reason. 
 2. Compensation. The Company will pay you a base salary at a rate of
$23,750.00 per month (annualized to $285,000 per year) effective December 9, 2013, in accordance with the Company’s standard payroll policies, including compliance with applicable withholding requirements. The first and last payment by the
Company to you will be adjusted, if necessary, to reflect a commencement or termination date other than the first or last working day of a pay period. 

  
 Connery, K- Promotion 

 
 



 









 



 
  

 In addition to your base salary, you will be eligible to participate in a Key Executive Bonus
Plan, which is targeted at $250,000 annually at 100% achievement of plan, pro-rated from the date of acceptance in the Chief Revenue Officer role. The Company will present you the details of the plan within two (2) weeks. 

3. Stock Ownership. Subject to the approval by the Company’s Board of Directors, you will be granted the equity based compensation
award(s) more fully described on Exhibit A attached hereto. 
 4. Benefits. This promotion does not change your benefit
status. 
 Sincerely, 
 BAZAARVOICE, INC. 

 
 



 
 Kathy Smith-Willman 
 Director
– People Relations 
 Agreed and Accepted: 
  

			
	Signature:	 	 /s/ Kelly Connery            


 Date: 12-9-13 

  
 Connery, K- Promotion
# CV3
(1) Adjusting Price $27.97 CWT

(2) Base Price $27.97 CWT

(3) Change from Base Price per CWT 0.00

(4) Price change per gallon $0.00

(Line (3) divide by 11.63 gallons/cwt)

(5) Price change per half gallon $0.00

Price change per quart $0.00 

Price change per pint $0.00

Price change per 14-oz pg. $0.00

Price change per 12-oz pg. $0.00

Price change per 1/3 qt. (10-oz) $0.00

Price change per half pint $0.00

(6) Price adjustment per gallon $0.00

Price adjustment per half gallon $0.00

Price adjustment per quart $0.00

Price adjustment per pint $0.00

Price change per 14-oz pg. $0.00

Price change per 12-oz pg. $0.00

Price adjustment per 1/3 qt. (10-oz) $0.00

Price adjustment per half pint $0.00

NOTE: Numbers in brackets are negative or decreases, all others are positive or increases.

Monthly EPA Calculation for Class I Milk (Clause 52.216-9032 Alt. I)

Based on California Marketing Area Federal Milk Order #51

 Effective Date: July 3rd, 2022
PRESIDER/PRESENTER(s)

Dr. José Romero (ACIP Chair)

Dr. Amanda Cohn (ACIP Executive Secretary, CDC)

9:15 Meningococcal

Introduction: Meningococcal Vaccines Session

Safety and immunogenicity of MenQuadfi

MenACWY-TT (MenQuadfi): EtR, GRADE, and Workgroup Considerations

Ms. Veronica McNally (ACIP, WG Chair)

Dr. Corey Robertson (Sanofi Pasteur)

Dr. Lucy McNamara (CDC/NCIRD)

Mr. Frank Whitlatch (CDC/NCIRD)

10:15 Influenza Vaccines

Introduction

WG Considerations and proposed recommendations

Dr. Robert Atmar (ACIP, WG Chair)

Dr. Lisa Grohskopf (CDC/NCIRD)

11:15

11:25

11:55 VOTES

Influenza Vaccines

VFC Vote

Meningococcal Vaccines

Dr. Lisa Grohskopf (CDC/NCIRD)

Mr. Frank Whitlatch (CDC/NCIRD)

12:10

12:40 Coronavirus Disease 2019 (COVID-19)

Overview of COVID-19 disease

SARS-CoV-2 immunology

U.S. COVID-19 epidemiology

Routine pediatric and influenza vaccination in the setting of COVID-19

Dr. John Brooks (CDC/NCHHSTP)

Dr. Natalie Thornburg (CDC/NCIRD)

Dr. Sara Oliver (CDC/NCIRD)

Dr. Melinda Wharton (CDC/NCIRD)

2:00

2:10 COVID-19 Vaccines

Introduction

COVID-19 vaccine development

Landscape of candidate COVID-19 vaccines

Dr. Beth Bell (ACIP, WG Chair)

Dr. Matthew Hepburn (Lead, Operation Warp Speed 

Vaccines)

Dr. Kathleen Neuzil (University of Maryland)

3:30

3:40 COVID-19 vaccine prioritization considerations

Work Group considerations and next steps

Dr. Sarah Mbaeyi (CDC/NCIRD)

Dr. Kathleen Dooling (CDC/NCIRD)

4:50 Agency Updates

CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, OIDP

5:00 Dr. Jeanne Santoli (CDC/NCIRD)

5:05

Acronyms

CDC

CMS

COVID-19

DoD

DVA

EtR

FDA

GRADE

HRSA

IHS

NCHHSTP

NCIRD

NCEZID

OIDP

SAGE

SARS-CoV-2

WG

Indian Health Service

National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID] 

National Center for Immunization & Respiratory Diseases [of CDC/OID] 

National Center for Emerging and Zoonotic Diseases [of CDC/OID]

Work Group

Strategic Advisory Group of Experts

Office of Infectious Disease and HIV/AIDS Policy

Severe acute respiratory syndrome coronavirus 2

Food and Drug Administration

Grading of Recommendations Assessment, Development and Evaluation

Department of Veterans Affairs

Evidence to Recommendations Framework

Health Resources and Services Administration

Department of Defense

Adjourn

Break

Lunch

Vaccine Supply Update

Coronavirus disease 2019

Wednesday, June 24

9:00 Welcome & Introductions

Public Comment 

Break

VFC Resolution Update: Meningococcal Vaccines

AGENDA ITEM

Final - June 16, 2020

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

June 24, 2020

Centers for Medicare and Medicaid Services 

Centers for Disease Control and Prevention

Break

page 1 of 2

This document has been archived for historical purposes. (6/16/2020)
Final - June 16, 2020

WHO

VE

World Health Organization

Vaccine Effectiveness

page 2 of 2

This document has been archived for historical purposes. (6/16/2020)
*DoD 4000.25-7-M, March 2004*

DLM 4000.25, Volume 4

**DIC FL1/FL2/GL1/GL2 FORMAT**

**RETAIL LOSS ALLOWANCE**

134

APPENDIX 3.18

1
Letter from the General Partner to Warrington extending Management Agreement



 Exhibit 10.1(b) 
 June 1, 2011 
 Warrington Asset Management 

200 Crescent Court — Suite 900 
 Dallas,
Texas 75201 
 Attention: Mr. Scott C. Kimple 
 Re: Management Agreement Renewal 
 Dear Mr. Kimple: 

We are writing with respect to your management agreement concerning the commodity pool to which reference is made below (the “Management
Agreement”). We are extending the term of the Management Agreement through June 30, 2012 and all other provisions of the Management Agreement will remain unchanged. 

 

	 	•	Warrington Fund L.P. 

 Please acknowledge
receipt of this modification by signing one copy of this letter and returning it to the attention of Ms. Jennifer Magro at the address above or fax to 212-296-6868. If you have any questions I can be reached at 212-296-1302. 

 

			
	Very truly yours,
	
	CERES MANAGED FUTURES LLC
		
	By:	 	/s/ Jennifer Magro
		 	Jennifer Magro
		 	Chief Financial Officer & Director

  

			
	WARRINGTON ASSET MANAGEMENT
		
	By:	 	/s/ Scott Kimple
	Print Name:	 	Scott Kimple
		
	JM/sr
SERVED: February 3, 2017 

U.S. DEPARTMENT OF TRANSPORTATION DEPARTMENT OF 

In The Matter Of: 

Sea Hawk Air, Inc. 

Respondent 

OFFICE OF HEARINGS TRA SPORTATION 

WASHINGTON, DC ZOll fEB -b p 1: 5~ 

) 

) 

) 

) 

) 

DOCKET OPERATIO S 

Docket No. FAA-2014-0865 

Case No. 2011NM730060 

DISMISSAL ORDER 

On February 2, 2017, the Respondent filed a Withdrawal of Hearing Request and 

Stipulation to Dismissal with Prejudice, stating that the parties had settled this matter. 

Pursuant to 14 C.F.R. § 13.215, a party may withdraw a request for a hearing without the 

consent of the administrative law judge at any time before or during a hearing. Upon such 

withdrawal, the administrative law judge shall dismiss the case with prejudice. 

IT IS HEREBY ORDERED: 

1. These proceedings are dismissed with prejudice. 

2. The hearing scheduled to begin on April 19, 2017 is cancelled. 

Attachment: Service List 

D6 UGLAS M. RAW ALD 

Administrative Law Judge 
SERVICE LIST - BY U.S. MAIL 

ORIGINAL & ONE COPY 

Federal Aviation Administration 

800 Independence Avenue, S.W. 

Washington, DC 20591 

Attention: Hearing Docket Clerk, AGC-430 

Wilbur Wright Building-Suite 2W1 0001 

John L. Wright, Respondent's Counsel 

The Law Office of John L. Wright, P.C. 

11705 Airport Way, Suite 307 

Broomfield, CO 80021 

TEL: 303-747-4000 

FAJ(:303-747-4001 

ONE COPY 

Kyle M. Lomazow, Complainant's Counsel 

Office ofRegional Counsel, Northwest Mountain Region, ANM-7 

Federal Aviation Administration 

1601 Lind Avenue, S.W. 

Renton, W A 98057 

TEL: 425-227-1847 

F~: 425-227-1007 

The Honorable Douglas M. Rawald, Administrative Law Judge 

Office of Hearings, M-20 

U.S. Department of Transportation 

1200New Jersey Avenue, S.E. (E11-310) 

Washington, DC 20590 

TEL: 202~366-5121 Staff Assistant 

FAX: 202-366-7536 

Docket No. FAA-2014-0865 

(Civil Penalty Action) 

1 Service was by U.S. Mail. For service in person or by expedited courier, use the following address: Federal 

Aviation Administration, 600 Independence Avenue, S.W., Wilbur WrightBuilding-Suite 2Wl000, Washington, 

DC 20591; Attention: Hearing Docket Clerk, AGC-430.
<page>
						  EXHIBIT 31.01


CERTIFICATIONS

I, Jeffrey A. Rothman, President of Demeter Management Corporation
("Demeter"), the general partner of the registrant, certify that:

1.		I have reviewed this quarterly report on Form 10-Q of the
registrant;

2.	Based on my knowledge, this report does not contain any
untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light
of the circumstances under which such statements were made,
not misleading with respect to the period covered by this
report;

3.		Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present
in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for,
the periods presented in this report;

4.		The registrant's other certifying officer and I are
responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) for the registrant and have:

a)	Designed such disclosure controls and procedures, or
caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material
information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in
which this report is being prepared;

b)	Evaluated the effectiveness of the registrant's disclosure
controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period
covered by this report based on such evaluation; and

c)	Disclosed in this report any change in the registrant's
internal control over financial reporting that occurred
during the registrant's most recent fiscal quarter (the
registrant's fourth fiscal quarter in the case of an
annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant's
internal control over financial reporting; and

<page>
5.		The registrant's other certifying officer and I have
disclosed, based on our most recent evaluation of internal
control over financial reporting, to the registrant's
auditors and the audit committee of Demeter's board of
directors (or persons performing the equivalent functions):

     a)	All significant deficiencies and material weaknesses in
the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect
the registrant's ability to record, process, summarize and
report financial information; and

     b)	Any fraud, whether or not material, that involves
management or other employees who have a significant role
in the registrant's internal control over financial
reporting.





Date:  November 15, 2004  /s/	Jeffrey A. Rothman
		Jeffrey A. Rothman
		President,
	Demeter Management Corporation,
No. 11-6349.

#### Eric Maurice Wright, Petitioner v. Jessica Symmes, Warden.

565 U.S. 1039, 132 S. Ct. 584,

181 L. Ed. 2d 429,

2011 U.S. LEXIS 8197.

November 14, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Eighth Circuit denied.
Exhibit 32.2



Certification Pursuant to

18 U.S.C.  Section 1350,

as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act
2002



In connection with
the Annual Report on Form 40-F of Sierra Metals Inc. (the “Company”) for the yearly period ended December 31, 2017,
as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ed Guimaraes, Chief Financial
Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, that, to the best of my knowledge:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange
Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|/s/ Ed Guimaraes |                        
|---------------- | -----------------------
|Name:            | Ed Guimaraes           
|Title:           | Chief Financial Officer
|Date:            | March 26, 2018         



The foregoing certificate
is solely for the purposes of compliance with the aforementioned Section 906 of the Sarbanes-Oxley Act 2002 and is not intended
to be used or relied upon for any other purposes.



A signed original of
this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished
to the SEC or its staff upon request.
No. 11-6542.

#### Stacey Laveral Williams, Petitioner v. United States.

565 U.S. 991, 132 S. Ct. 531,

181 L. Ed. 2d 372,

2011 U.S. LEXIS 7742.

October 31, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.

Same case below, 431 Fed. Appx. 321.
EXHIBIT 10.31


 


Description of Oral Loan Agreement between
Consumer Capital Group and Jianmin Gao


 


Party A: Consumer Capital Group


 


Party B: Jianmin Gao


 


Party A and B are related parties, with
Party B as the CEO and CFO of Party A. Party A and B negotiated and agreed that Party B shall provide Party A operating or working
capital during Party A’s production operations. Party A shall pay no interests as a result of this loan arrangement to Party
B. Party A shall provide no assets as a security for the loan received from Party B under this agreement. Party A shall pay the
amount of the loan upon Mr. Gao’s request.


 


This Agreement is valid during the operational
period of Party A.
# Vaccination by 08 months

# Vaccination by 13 months
Extension Letter Amendment



 Exhibit 10.23 

 

			
	



	  	 AVEO Pharmaceuticals, Inc.
 75 Sidney Street
 Cambridge, MA 02139

 
 www.aveopharma.com


 October 31, 2011 
 Raju Kucherlapati, PhD 
 6 Wildflower Lane 
 Weston, MA 02493 
 Re: Consulting and Scientific Advisory Board Agreement by and between Raju
Kucherlapati, PhD and AVEO Pharmaceuticals, Inc. effective as of January 1, 2010 (the “Agreement”) 
 Dear Dr. Kucherlapati,

 It is hereby agreed that Section 2 of the Agreement shall be amended to extend the Consultation Period through and including
December 31, 2013 unless sooner terminated in accordance with Section 11 of the Agreement. All other terms and obligations under the Agreement shall remain the same. 

 

	
	Sincerely,
	
	 /s/ Murray O. Robinson

	Murray O. Robinson, PhD
	Senior Vice President, Translational Research
	Chair of the Scientific Advisory Board

  

							
	Agreed and Acknowledged:	 	 	 	 	 	 
				
	 /s/ Raju Kucherlapati
	 		 	 November 3, 2011
	 	
	Raju Kucherlapati, PhD	 		 	Date